Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease
Open Access
- 26 May 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 27 (2), 709-715
- https://doi.org/10.1093/ndt/gfr288
Abstract
Background.Hypogonadism or testosterone deficiency is a prevalent condition in men with chronic kidney disease (CKD). Testosterone stimulates erythropoiesis via production of haematopoietic growth factors and possible improvement of iron bioavailability. We hypothesized that testosterone deficiency predisposes to anaemia and reduced responsiveness to erythropoiesis-stimulating agents (ESAs) in CKD men.Materials and methods.We studied associations between endogenous testosterone and haemoglobin in 239 ESA-naïve nondialysed CKD Stages 1–5 male patients. Additionally, we studied associations between endogenous testosterone levels and ESA dose (U/kg/week) in 126 ESA-treated men undergoing haemodialysis (HD).Results.Among ESA-naïve males, patients with anaemia presented lower testosterone values. Endogenous testosterone was negatively associated with haemoglobin levels in uni- and multivariate models. Testosterone-deficient patients (total testosterone <10 nmol/L) were 5.3 (95% confidence interval 2.2–12.5) times more likely to be anaemic (Hb < 13.0 g/dL) than testosterone-sufficient patients. In ESA-treated men undergoing HD, higher ESA doses (above the median value of 121 IU/kg body weight/week) are associated with lower testosterone levels and higher percentage of hypochromic red blood cells (RBC). The inverse association between testosterone levels and ESA doses persisted after multivariate adjustment for age, sex hormone-binding globulin, comorbidities, C-reactive protein and s-albumin but was lost after further adjustment for iron medication and hypochromic RBC.Conclusions.Hypogonadism may be an additional cause of anaemia and reduced ESA responsiveness in men with CKD. Our results raise the possibility that restoration of testosterone levels in hypogonadal CKD males may translate into lower prevalence of anaemia and better ESA responsiveness.Keywords
This publication has 41 references indexed in Scilit:
- Testosterone Suppresses Hepcidin in Men: A Potential Mechanism for Testosterone-Induced ErythrocytosisJournal of Clinical Endocrinology & Metabolism, 2010
- Sex Steroid Hormones in Older Men: Longitudinal Associations with 4.5-Year Change in Hip Bone Mineral Density—The Osteoporotic Fractures in Men StudyJournal of Clinical Endocrinology & Metabolism, 2010
- Adverse Events Associated with Testosterone AdministrationNew England Journal of Medicine, 2010
- Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-AnalysisJournal of Clinical Endocrinology & Metabolism, 2010
- Effects of Transdermal Testosterone on Bone and Muscle in Older Men with Low Bioavailable Testosterone Levels, Low Bone Mass, and Physical FrailtyJournal of the American Geriatrics Society, 2010
- Comorbidity and Acute Clinical Events as Determinants of C-Reactive Protein Variation in Hemodialysis Patients: Implications for Patient SurvivalAmerican Journal of Kidney Diseases, 2009
- The Effect of Altitude on Dosing and Response to Erythropoietin in ESRDJournal of the American Society of Nephrology, 2008
- Erythropoiesis‐stimulating agent hyporesponsiveness (Review Article)Nephrology, 2007
- Prevalence of hypogonadism in male patients with renal failurePublished by Oxford University Press (OUP) ,2006
- Low Testosterone Levels and the Risk of Anemia in Older Men and WomenArchives of Internal Medicine, 2006